Literature DB >> 18324611

Review of peripheral neuropathy in plasma cell disorders.

Jeannine Silberman1, Sagar Lonial.   

Abstract

Peripheral neuropathy (PN) occurs frequently in patients with plasma cell disorders, a heterogeneous group of disorders resulting from the unregulated production of monoclonal proteins. This occurs both due to the dysproteinemia itself and as a consequence of the therapies used to treat the underlying plasma cell disorder. This comprehensive review of PN associated with plasma cell disorders will address both disease and therapy related PN, its pathogenesis and management with particular attention to multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) and amyloidosis. An understanding of this topic is critical for health care providers treating patients with plasma cell disorders due to the high frequency with which it occurs, the implications it has on selecting therapies for the underlying disorder and to best guide management of the neuropathy itself.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324611     DOI: 10.1002/hon.845

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  15 in total

1.  Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density.

Authors:  Alyssa K Kosturakis; Zijing He; Yan Li; Jessica A Boyette-Davis; Nina Shah; Sheeba K Thomas; Haijun Zhang; Elisabeth G Vichaya; Xin Shelley Wang; Gwen Wendelschafer-Crabb; William R Kennedy; Donald A Simone; Charles S Cleeland; Patrick M Dougherty
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Clinical reasoning: a 40-year-old man with CIDP-like illness resistant to treatment.

Authors:  Rajat Lahoria; Chafic Karam; Angela Dispenzieri; P James B Dyck
Journal:  Neurology       Date:  2013-09-03       Impact factor: 9.910

3.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

4.  Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome.

Authors:  Camila Catherine Aquino; Barbara Connolly; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2018-07-19

Review 5.  Development of POEMS syndrome after an initial manifestation of solitary plasmacytoma.

Authors:  Motohiro Shindo; Kazuya Sato; Masayo Yamamoto; Yasumichi Toki; Mayumi Hatayama; Satoshi Ito; Kazuhiko Ichiki; Naoka Okamura; Takaaki Hosoki; Katsuya Ikuta; Junki Inamura; Shinji Watanabe; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2011-05-07       Impact factor: 2.490

6.  An observational study assessing peripheral neuropathy related to multiple myeloma.

Authors:  C Leone; V Federico; S La Cesa; E Russo; G Di Stefano; P Finsinger; R Labriola; G Cruccu; M T Petrucci; A Truini
Journal:  Neurol Sci       Date:  2016-03-09       Impact factor: 3.307

Review 7.  An update on monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

8.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Pathological crystallization of human immunoglobulins.

Authors:  Ying Wang; Aleksey Lomakin; Teru Hideshima; Jacob P Laubach; Olutayo Ogun; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

Review 10.  Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

Authors:  Andreas J Steck; Adam Czaplinski; Susanne Renaud
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.